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This clinical study reports that blood levels of the
pro-inflammatory mediator platelet-activating factor
(PAF) did not change in colorectal cancer patients. In
contrast, plasma levels of two enzymatic activities,
one implicated in PAF production (i.e. phospholipase
A2) and one in PAF degradation (i.e. PAF acetylhy-
drolase activity) were significantly elevated.
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Platelet-activating factor (PAF) is a lipidic molecule
that sparks a wide range of immunoregulatory
actions.
1 PAF derives from membrane precursors,
1-alkyl-2-acyl-glycero-3-phosphocholine. The action
of a phospholipase A2 (PLA2)-dependent process
generates the lyso-PAF precursor, and the subsequent
acetylation of the lyso compound results in the PAF
molecule. PAF concentrations are regulated by an
acetylhydrolase activity (AHA) found both in plasma
and in serum.
1 Despite no evident role in lung cancer,
its potential role in breast cancer is suggested.
2
Recently elevated levels of AHA and PLA2 have
been found in tumour tissues of colorectal cancer
patients.
3 PAF can generate biological responses
detectable at levels of 10 fM. It is thus of evidence
that regulating PAF levels is important since elevated
or decreased levels of PAF might result in patho-
logical effects. The present study was designed to
determine whether investigating circulating levels of
PAF, soluble PLA2, and AHA might be of clinical
interest for colorectal cancer patients.
This study followed the rules edited by the French
National Ethics Committee, and the Local Ethics
Committee has approved them. This was a prospect-
ive study including 29 patients with a newly diag-
nosed and histologically confirmed primary color-
ectal cancer. There were 18 men and 11 women with
a median age of 76 years (range, 45/95 years). No
patient received chemotherapy or irradiation before
surgery. Blood samples were harvested at the time
surgery for PAF, PLA2 and AHA determinations. Blood
samples from 20 healthy subjects (14 men and six
women; mean age, 75 years) were investigated as
controls. Two millilitres of blood were ethanol
extracted (80% final), purified, and assayed for PAF
activity by aggregation of washed rabbit platelets.
3
Plasma AHA levels (expressed as nanomoles of PAF
degraded per minute per millitre of plasma) was
determined by investing the degradation of [
3H]-
labelled-PAF.
3 Soluble PLA2 plasma levels (expressed
as units per millilitre) were assessed by enzyme-
linked immunosorbent assay according to the man-
ufacturer’s recommendations (R&D Systems Europe,
Ltd, Oxon, UK).
3 Results are presented as the mean
9 /standard error of the mean, and were subjected to
a non-parametric Mann/Whitney U-test. p B/0.05
was considered significant.
As shown in Fig. 1, no significant difference
(p/0.8) was documented between blood PAF levels
of colorectal patients (9.69 /2.1 pg/ml, n/29) and
healthy controls (10.49 /2.4 pg/ml, n/20). In con-
trast, plasma AHA (the PAF catabolic enzyme) was
significantly (p/0.0004) enhanced in patients
(65.39 /4.8 nmol/ml/min, n/29) as compared with
controls (43.89 /3.4 nmol/ml/min, n/20). Their
plasma soluble PLA2 (the key enzyme for PAF bio-
synthesis) levels were also significantly (p/0.03)
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53elevated (70.69 /6.5 U/ml versus 57.99 /3.1 U/ml for
patients and controls, respectively).
Our results indicate that blood PAF amounts of
colorectal cancer patients were not different at the
time of surgery from those of healthy individuals.
Since blood PAF has a half-life of few minutes in vivo,
its circulating levels are reflective of the balance
between its production and degradation. Two enzy-
matic activities, one implicated in PAF production
(i.e. soluble PLA2) and one in PAF degradation
(i.e. AHA), were significantly elevated in colorectal
cancer patients as compared with healthy individuals.
Previous data have reported elevated circulating PLA2
levels in patients with advanced cancer.
4 However,
the plasma PLA2 increase is modest and difficult to
interpret since this enzyme is also elevated in a wide
range of inflammatory diseases.
5 Similarly to PLA2,
plasma AHA levels are elevated in colorectal cancer
patients. However, the AHA increase is modest and
sheds little light on its role in colorectal cancer
patients since this enzyme is also elevated in numer-
ous non-cancer diseases.
1 Whatever the origin of
these elevated plasma PLA2 and AHA levels, it is of
evidence that assessment of their plasma concentra-
tions cannot be used as a diagnostic and/or prog-
nostic marker for colorectal cancer patients. In
conclusion, and indirectly suggesting that PAF might
play a role in colorectal cancer, plasma soluble PLA2
and AHA levels were higher in patients as compared
with healthy controls. These results strengthen recent
data obtained with tumour tissues of colorectal
cancer patients.
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FIG. 1. Blood PAF (A), plasma AHA (B) and soluble PLA2 (C)
levels in colorectal cancer patients. Mean9 /standard error of
the mean of 29 colorectal cancer patients and 20 healthy
controls. Differences between groups were assessed using
the Mann/Whitney U-test.
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